August, 2017

Top Attributes Driving Asthma Access Decisions

Net pricing and outcomes data most drive health plan access decisions for branded asthma drugs; clinical data most drive medical group choices.

August, 2017

Commercial plans prioritize cost reduction

Biopharmaceutical companies can leverage the importance commercial plans place on clinical goals by offering compelling, clinically differentiating value propositions for their products in order to direct plans to shift their focus beyond unit product costs to total disease/care management

August, 2017

Payers Will Decrease Reliance on PBMs If They Fail To Improve their Services by Developing Specific Capabilities

The majority of health plans and employers anticipate accessing important services and capabilities through internal development or external contracting if PBM offerings remain unsatisfactory.

August, 2017

Prevalence of Base-Price Discount Contracts Diminishes as IDNs Increase Experimentation with Different Contracts

IDNs favor outcomes-based contracts for categories in which outcomes can be objectively measured. While outcomes-based contracts are still uncommon, IDNs most prefer them for antibiotics, COPD, hepatitis C, and multiple sclerosis agents.

August, 2017

Pricing, Net Costs Most Important Attributes in Plan Access Decisions

Pricing and overall net costs are the most important attributes in health plan access decisions for psoriasis drugs; medical groups are more driven by safety and quality-of-life metrics.

July, 2017

Pricing and Ability to Reduce Exacerbations are Most Important Attributes in Stakeholder Access Decisions

Market Access Brand Value Proposition | Research Released July 2017

Health plans acknowledge that lower net pricing is a primary driver of access decisions in COPD, and predictive analysis confirms this.

We'll say to the manufacturers, we think you're more similar than different. So from a financial perspective, now it's a horse race based on best pricing or other unique contract terms. – National Plan Pharmacy

July, 2017

Evolving Market Dynamics Will Continue to Influence and Limit Access to Branded MS Drugs by 2019

Brand Access Marketplace Dynamics   |   Research Released July 2017

Availability of new brands and potential entrance of multisource generics will compel stakeholders to intensify management tactics to further narrow preferred branded MS drugs.

Biopharmaceutical companies that support stakeholder objectives of achieving high-quality, cost-effective long-term care for MS patients will benefit from improved relations and likely sustain optimal access for their brands.

July, 2017

Stakeholder Actions to Influence Oncology Drug Use

Typically Interdependent, Potentially Conflicting

July, 2017

Select Emerging PBMs Gain Market Share

Express Scripts and CVS Caremark Maintain Lead

March, 2017

HTA Agencies Differ Based on Governance, Functional Role, and Use of HTA to Inform Decisions

Biopharmaceutical companies must recognize the differential application of common HTA principles/methodologies within each agency, tailoring tactics to individual setting requirements

Pages

Subscribe to RSS - blamb@healthstrategies.com's blog

Disclaimer

 

Please complete the form to have this document sent to your email.

 

Please complete the form to have this document sent to your email.